Semaglutide(Ozempic) is a glucagon-like peptide-1 analogue for once-weekly subcutaneous treatment of type 2 diabetes.Semaglutide is a pharmaceutical drug which is used for the
treatment of type 2 diabetes. Semaglutide has demonstrated the potential to improve the treatment of type 2 diabetes and the positive recommendation from the Advisory Committee marks an important
step towards making semaglutide available to adults with type 2 diabetes in the US. Semaglutide(Ozempic), a newly once-weekly glucagon like peptide-1 (GLP-1) receptor agonist, has showed
a favorable effect on glycaemic control andweight loss